News

Public · Published

Merck & Company, Inc. Stock 12‑Month Price Target Raised to $162.25, Implies 12% Upside

Analysts' average 12-month price target for Merck & Company, Inc. rose from $160.56 to $162.25. Based on the Nov. 3 closing price, the revised target implies approximately 12% potential upside. The consensus rating remains Buy among 30 analysts, with 21 Buys, eight Holds and one Sell.

Published:

Updated:

What happened

Analysts’ average 12-month price target for Merck & Company, Inc. rose from $160.56 to $162.25. Based on the Nov. 3 closing price, the revised target implies approximately 12% potential upside. The consensus rating remains Buy among 30 analysts, with 21 Buys, eight Holds and one Sell.

Confirmed

Global impact / market context

The higher target signals a modest improvement in analysts’ expected value for Merck shares, but it is a forecast rather than a promised return. If investors act on the more positive view, buying could support the share price; the article provides no evidence of changed company sales or costs.

Analyst inference

The 24 analysts’ average target is $162.25, while individual forecasts span $105 to $186 per share, showing considerable disagreement. The separate rating count covers 30 analysts and remains Buy overall; these views describe expectations, not confirmed changes in Merck’s business or financial results.

Confirmed

What to watch

  1. Check whether later analyst updates raise or lower the average target, and whether forecast changes cite concrete revisions to expected sales, costs, or earnings. Analyst inference
  2. Compare the share price with the $162.25 average target and the Nov. 3 closing-price reference; the stated 12% upside is tied to that reference point. Confirmed
  3. Watch for changes in the 30-analyst rating mix—currently 21 Buys, eight Holds and one Sell—to see whether the overall Buy consensus strengthens or weakens. Analyst inference

Evidence

  • Original source link unavailable